Literature DB >> 3035737

Effect of monocrotaline ingestion on the distribution of protein and angiotensin converting enzyme activity in the rat lung.

D J Shale, M S Wiseman, W O Cookson.   

Abstract

The alveolar accumulation of protein and angiotensin converting enzyme activity was compared with the development of right ventricular hypertrophy in male rats after different periods of monocrotaline exposure. Total doses of monocrotaline were varied by dividing the animals into three groups in which ingestion was limited to three, seven, and 15 days. These groups were studied 21 days after the start of monocrotaline exposure and compared with a group treated continuously for 28 days. The total lung weight increased after three or more days of treatment, while after seven days there was significant alveolar accumulation of protein, which was paralleled by an increase in angiotensin converting enzyme activity in alveolar lavage fluid. Identical changes also occurred after 15 and 28 days of exposure to monocrotaline. Lung angiotensin converting enzyme activity was decreased after three days' ingestion of monocrotaline and did not alter further with longer periods of exposure. None of these effects of monocrotaline in the three and seven day treatment groups was associated with right ventricular hypertrophy, which occurred only in animals treated for 15 or more days. The effects of monocrotaline ingestion on the lung were dose related and had no causal relationship to the development of right ventricular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3035737      PMCID: PMC460539          DOI: 10.1136/thx.41.12.914

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

Review 1.  Measurement of soluble proteins in lung secretions.

Authors:  R A Stockley
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

2.  Lung angiotensin converting enzyme activity in monocrotaline pulmonary hypertension.

Authors:  P M Keane; J M Kay
Journal:  Thorax       Date:  1984-02       Impact factor: 9.139

3.  Changes in angiotensin-converting enzyme activity in lungs damaged by the pyrrolizidine alkaloid monocrotaline.

Authors:  W M Lafranconi; R J Huxtable
Journal:  Thorax       Date:  1983-04       Impact factor: 9.139

4.  The effect of a pyrrolizidine alkaloid, monocrotaline, and a pyrrole, dehydroretronecine, on the biochemical functions of the pulmonary endothelium.

Authors:  R Huxtable; D Ciaramitaro; D Eisenstein
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

5.  Lung angiotensin converting enzyme activity in rats with pulmonary hypertension.

Authors:  P M Keane; J M Kay; K L Suyama; D Gauthier; K Andrew
Journal:  Thorax       Date:  1982-03       Impact factor: 9.139

6.  Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension.

Authors:  J M Kay; P M Keane; K L Suyama; D Gauthier
Journal:  Thorax       Date:  1982-02       Impact factor: 9.139

7.  Effect of acute lung injury on angiotensin converting enzyme in serum, lung lavage, and effusate.

Authors:  M A Hollinger; S N Giri; S Patwell; J E Zuckerman; A Gorin; G Parsons
Journal:  Am Rev Respir Dis       Date:  1980-02

8.  Development of Crotalaria pulmonary hypertension: hemodynamic and structural study.

Authors:  B Meyrick; W Gamble; L Reid
Journal:  Am J Physiol       Date:  1980-11

9.  Angiotensin converting enzyme and endotoxin induced lung damage in the mouse.

Authors:  W O Cookson; M S Wiseman; D J Shale
Journal:  Thorax       Date:  1985-10       Impact factor: 9.139

10.  Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats.

Authors:  T Sugita; T M Hyers; I M Dauber; W W Wagner; I F McMurtry; J T Reeves
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1983-02
View more
  1 in total

1.  Monocrotaline pyrrole-induced changes in angiotensin-converting enzyme activity of cultured pulmonary artery endothelial cells.

Authors:  C M Hoorn; R A Roth
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.